DUBLIN – Morphosys AG is, after a long haul, finally within touching distance of having one of its Hucal antibodies on the market, following a BLA filing in psoriasis by partner Janssen Research & Development LLC in support of guselkumab, which targets the p19 subunit of interleukin-23 (IL-23.).